It was recently reported that menin “reads” (selectively binds to) H3K79me2 via its finger domains, allowing for coincident interaction via its palm and N-terminal domains with MLL1 and LEDGF (61); small-molecule disruptors of this interaction could therefore be used in place of or in combination with menin-MLL1 inhibitors in MLLr leukemias or NPM1c AML. The gene discussed is MEN1; the disease is acute myeloid leukemia.